🔥 We have been featured on Shark Tank India.Episode 13

🔥 We have been featured on Shark Tank India

logologo
Search anything
Ctrl+K
gift
arrow
WhatsApp Icon

Stock Summary and Key Metrics













Investment Checklist



























Technicals

Oscillators

BearishNeutralBullish

Bearish

Bearish

5

Neutral

5

Bullish

4

Overall

BearishNeutralBullish

Bearish

Bearish

31

Neutral

5

Bullish

10

Moving Averages

BearishNeutralBullish

Bearish

Bearish

26

Neutral

0

Bullish

6

Overall

BearishNeutralBullish

Bearish

Bearish

31

Neutral

5

Bullish

10

Forecasts

No ConstituentsNo Constituents

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Ask AI

mockupmockup

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

View Standalone

Total Figures
QoQ Changes
Total Figures
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales9710277808973575058
Expenses909168718063625260
Operating Profit6.98128.208.708.7710-4.47-2.84-1.43
OPM %7.1711.4410.7110.889.8913.91-7.79-5.73-2.44
Other Income0.000.050.020.140.140.210.000.030.11
Interest3.313.953.753.673.494.034.045.034.05
Depreciation3.633.863.883.974.054.704.484.634.46
Profit Before Tax0.043.930.581.201.371.63-13-12-9.84
Tax %-1,150.0010.18-362.07-124.175.8496.93-6.1541.060.00
Net Profit0.503.532.682.691.290.06-14-7.35-9.84
EPS in Rs0.312.231.701.700.810.04-8.72-4.64-6.21

Consolidated Profit Loss (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2024Mar 2025TTM
Sales369318299
Expenses351282276
Operating Profit173623
OPM %4.7211.267.74
Other Income0.100.50NaN
Interest141515
Depreciation151717
Profit Before Tax-114.79-8.80
Tax %18.08-40.43-10.91
Net Profit-9.076.72-9.76
EPS in Rs4.25-19.53
Dividend Payout %0.000.00

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2024Mar 2025
Equity Capital1616
Reserves120133
Borrowings9889
Other Liabilities99128
Total Liabilities334366
Fixed Assets148163
CWIP7.742.69
Investments0.000.00
Other Assets178201
Total Assets334366

Consolidated Cash Flows (in ₹ Crores)

View Standalone

View Standalone

Total Figures
YoY Changes
Total Figures
Mar 2024Mar 2025
Cash from Operating Activity3.9143
Cash from Investing Activity-12-19
Cash from Financing Activity5.23-22
Net Cash Flow-2.691.41

Shareholdings

Shareholding History

Quarterly
Yearly
Quarterly
Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters50.32%50.32%50.32%50.32%50.32%50.32%50.30%50.30%50.30%50.30%50.30%35.64%
FIIs0.10%0.10%0.10%0.10%0.26%0.21%0.11%0.11%0.46%0.53%0.11%0.13%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public49.58%49.58%49.58%49.58%49.42%49.47%49.58%49.58%49.23%49.16%49.58%64.22%
Total Shareholders17,94317,89017,97818,61019,17319,31219,50819,67919,69719,72819,88121,227

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

professionalIcon

Upgrade

transaction-premiumtransaction-premium

Projection

No ConstituentsNo Constituents

Documents

Presentations
Concalls
Reports
Presentations
iconiconicon

Investor Presentation

Q1 FY17

iconiconicon

Investor Presentation

Q4 FY16

iconiconicon

Investor Presentation

Q3 FY16

lock

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type




























































AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Ask AI

ai-corner-premiumai-corner-premium
ai-corner-premiumai-corner-premium

Frequently Asked Questions about Mangalam Drugs and Organics Ltd

Mangalam Drugs and Organics Ltd (MANGALAM) is currently trading at 29.37 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Mangalam Drugs and Organics Ltd is a chemical manufacturing company specializing in active pharmaceutical ingredients, perfumery, dye intermediates, and bulk drug intermediates. Established in 1972, its key facilities are located in Vapi and Sangamner. The company has a strong manufacturing setup with significant production capacity expansions over the years, signaling its strategic focus on growth and scale in bulk drugs. Mangalam has demonstrated a commitment to innovation by establishing an Intellectual Property Rights cell and securing WHO approvals for several active pharmaceutical ingredients since 2017. The firm's extensive product portfolio includes chloroquine phosphate, aluminum chloride anhydrous, and other API intermediaries, positioning it as a versatile player in the pharma industry.

Over the past 52 weeks, Mangalam Drugs and Organics Ltd has traded between a low of ₹22.70 and a high of ₹94.80. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Mangalam Drugs and Organics Ltd has a market capitalization of approximately 46.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Mangalam Drugs and Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -1.50 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 46.49 Cr, Mangalam Drugs and Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Mangalam Drugs and Organics Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Mangalam Drugs and Organics Ltd is -1.50. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.